Millenium to Evaluate Biacore's Prototype Drug Discovery Technology

Biacore International AB (Uppsala, Sweden) has signed a collaborative agreement with Millennium Pharmaceuticals Inc. (Cambridge, MA). Under the agreement, Millenium will evaluate Biacore's new prototype instrumentation for application in drug discovery. Millenium will utilize the instrument—which is based on novel, biomolecular binding analysis technology—to accelerate the identification of potential drug targets and small molecule lead candidates.

Under terms of the agreement, Biacore will give Millennium Pharmaceuticals a prioritized option for both involvement in subsequent development programs and for accessing the new platform product prior to its commercial launch.

Millennium is a drug discovery and development company that employs large-scale genetics, genomics, high-throughput screening, and informatics in an integrated science and technology platform.

Biacore International AB is focused on the detection and monitoring of biomolecular binding using affinity-based biosensor technology.

For more information: Lars-Göran Andrén, President and CEO, Biacore International AB, Rapsgatan 7, S-754 50 Uppsala, Sweden. Tel: +46-18-675-700. Fax: +46-18-150-110.

Edited by Jim Pomager